{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:56:59Z","timestamp":1786719419586,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS-IRG"],"award-info":[{"award-number":["ACS-IRG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["4R01CA160233-05"],"award-info":[{"award-number":["4R01CA160233-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study characterizes the tumor-immune microenvironment in pretreatment, localized anal squamous cell carcinoma (ASCC), including two markers that have not previously been studied in ASCC: indoleamine 2,3 dioxygenase 1 (IDO1) and human leukocyte antigen (HLA) class I.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Retrospective review identified 63 patients with ASCC receiving definitive chemoradiation between 2005 and 2016 with pretreatment tissue available. Immunohistochemistry was used to quantify cluster of differentiation 8 (CD8), programmed cell death protein 1, programmed death-ligand 1, HLA class I, and IDO1. Cox proportional hazards models evaluated associations between outcomes and immune markers, controlling for clinical characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>With a median follow-up of 35\u2009months, 3-year overall survival was 78%. The only marker found to have a robust association with outcome was tumor IDO1. In general, the percentage of tumor cells expressing IDO1 was low (median 1%, interquartile range 0%\u201320%); however, patients with &amp;gt;50% of tumor cells expressing IDO1 had significantly worse overall survival (hazard ratio [HR] 4.7, p\u2009=\u2009.007) as well as higher local recurrence (HR 8.6, p\u2009=\u2009.0005) and distant metastasis (HR 12.7, p\u2009=\u2009.0002). Tumors with &amp;gt;50% IDO1 were also more likely to have the lowest quartile of CD8 infiltrate (&amp;lt;40 per high-power field, p\u2009=\u2009.024).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ASCC has a diverse immune milieu. Although patients generally do well with standard therapy, IDO1 may serve as a prognostic indicator of poor outcome and could help identify a patient population that might benefit from IDO-targeted therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0794","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T19:55:48Z","timestamp":1550001348000},"page":"e275-e283","source":"Crossref","is-referenced-by-count":28,"title":["High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy"],"prefix":"10.1093","volume":"24","author":[{"given":"Devarati","family":"Mitra","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora K.","family":"Horick","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane G.","family":"Brackett","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham & Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Mamon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham & Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna R.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill N.","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Ting","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Wo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"key":"2021122507122026300_R1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: A review and synthetic analysis","volume":"13","author":"Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122507122026300_R2","volume-title":"Surveillance, Epidemiology, and End Results Program U.S. Population Data \u2013 1969\u20132016","author":"National Cancer Institute","year":"2017"},{"key":"2021122507122026300_R3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.canep.2015.10.008","article-title":"Trends in incidence and survival for anal cancer in New South Wales, Australia, 1972-2009","volume":"39","author":"Soeberg","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"2021122507122026300_R4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bjc.6603175","article-title":"Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002","volume":"95","author":"Brewster","year":"2006","journal-title":"Br J Cancer"},{"key":"2021122507122026300_R5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122507122026300_R6","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L","article-title":"Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal","volume":"51","author":"Nigro","year":"1983","journal-title":"Cancer"},{"key":"2021122507122026300_R7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122507122026300_R8","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122507122026300_R9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","article-title":"Anal carcinoma: Impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial","volume":"87","author":"Gunderson","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122507122026300_R10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.20","article-title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53","volume":"112","author":"Meulendijks","year":"2015","journal-title":"Br J Cancer"},{"key":"2021122507122026300_R11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2014.11.013","article-title":"Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer","volume":"113","author":"Koerber","year":"2014","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2021122507122026300_R12","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507122026300_R13","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-16-2017","article-title":"Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma","volume":"23","author":"Mouw","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122507122026300_R14","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1158\/1078-0432.CCR-05-2434","article-title":"Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma","volume":"12","author":"Grabenbauer","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122507122026300_R15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jso.23998","article-title":"Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma","volume":"112","author":"Hu","year":"2015","journal-title":"J Surg Oncol"},{"key":"2021122507122026300_R16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"key":"2021122507122026300_R17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"2021122507122026300_R18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"Oncoimmunology"},{"key":"2021122507122026300_R19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S153965","article-title":"Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients","volume":"10","author":"Zhao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2021122507122026300_R20","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122507122026300_R21","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122507122026300_R22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122507122026300_R23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","article-title":"Biomarkers of response to PD-1\/PD-L1 inhibition","volume":"116","author":"Maleki Vareki","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122507122026300_R24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"2021122507122026300_R25","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1038\/onc.2008.35","article-title":"Immune escape as a fundamental trait of cancer: Focus on IDO","volume":"27","author":"Prendergast","year":"2008","journal-title":"Oncogene"},{"key":"2021122507122026300_R26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2008-11-191197","article-title":"Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells","volume":"114","author":"Chung","year":"2009","journal-title":"Blood"},{"key":"2021122507122026300_R27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","article-title":"Targeting the indoleamine 2,3-dioxygenase pathway in cancer","volume":"3","author":"Moon","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2021122507122026300_R28","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6603477","article-title":"Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer","volume":"95","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"key":"2021122507122026300_R29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival","volume":"14","author":"Ino","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122507122026300_R30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2407-14-335","article-title":"Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: A retrospective cohort study","volume":"14","author":"Choe","year":"2014","journal-title":"BMC Cancer"},{"key":"2021122507122026300_R31","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122507122026300_R32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2010.02.028","article-title":"Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy","volume":"117","author":"Inaba","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2021122507122026300_R33","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.981457","article-title":"Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival","volume":"4","author":"Ferns","year":"2015","journal-title":"Oncoimmunology"},{"key":"2021122507122026300_R34","doi-asserted-by":"crossref","first-page":"21319","DOI":"10.1038\/srep21319","article-title":"Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"2021122507122026300_R35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00428-012-1340-x","article-title":"Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma","volume":"462","author":"Ye","year":"2013","journal-title":"Virchows Arch"},{"key":"2021122507122026300_R36","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J Immunol"},{"key":"2021122507122026300_R37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0161-5890(98)00026-1","article-title":"Why certain antibodies cross-react with HLA-A and HLA-G: Epitope mapping of two common MHC class I reagents","volume":"35","author":"Sernee","year":"1998","journal-title":"Mol Immunol"},{"key":"2021122507122026300_R38","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.171.4.1918","article-title":"Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide","volume":"171","author":"Perosa","year":"2003","journal-title":"J Immunol"},{"issue":"suppl 4","key":"2021122507122026300_R39","doi-asserted-by":"crossref","first-page":"368a","DOI":"10.1200\/jco.2011.29.4_suppl.368","article-title":"Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"29","author":"Kachnic","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122507122026300_R40","first-page":"34","article-title":"Tryptophan-degrading enzymes in tumoral immune resistance","volume":"6","author":"Baren","year":"2015","journal-title":"Front Immunol"},{"key":"2021122507122026300_R41","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"Oncoimmunology"},{"key":"2021122507122026300_R42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e275\/41917666\/oncolo_24_6_e275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e275\/41917666\/oncolo_24_6_e275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:13:22Z","timestamp":1640416402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/e275\/6439300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,12]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0794","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2019,2,12]]}}}